A survey found that 68% of 156 executives who direct or influence marketing at U.S. and European drugmakers think the business model is broken. Seventy-six percent said budget pressure and health-system pricing will be the industry's biggest challenge for the next two years. Others expect issues to include having to prove cost-effectiveness and dealing with market-access restriction.
Execs: Pharma business model is broken
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|